Identification of a synovial fibroblast-specific protein transduction domain for delivery of apoptotic agents to hyperplastic synovium

Zhibao Mi, Xiaoli Lu, Jeffrey C. Mai, Bobby G. Ng, Guiqiang Wang, Eric R. Lechman, Simon C. Watkins, Hannah Rabinowich, Paul D. Robbins

Research output: Contribution to journalArticlepeer-review

64 Scopus citations


Synovial hyperplasia, resulting in erosion of cartilage and bone, represents one of the major pathologies associated with rheumatoid arthritis. To develop an approach for efficient delivery of proteins or agents to synovium to induce targeted apoptosis of hyperplastic synovial tissue, we have screened an M13 peptide phage display library for synovial-specific transduction peptides. We identified a novel synovial-targeted transduction peptide, HAP-1, which is able to facilitate specific internalization of protein complexes into human and rabbit synovial cells in culture and rabbit synovial lining in vivo. HAP-1 and a non-tissue-specific cationic protein transduction domain, PTD-5, were fused to an antimicrobial peptide, (KLAK)2, to generate two proapoptotic peptides termed DP2 and DP1, respectively. Administration of these peptides was able to induce apoptosis of rabbit and human synovial cells in culture, with DP2 inducing synovial cell-specific apoptosis. Intra-articular injection of DP1 and DP2 into arthritic rabbit joints with synovial hyperplasia induced extensive apoptosis of the hyperplastic synovium, while reducing the leukocytic infiltration and synovitis. These results suggest that proapoptotic peptides and, in particular, DP2 can be clinically useful for treatment of synovial hyperplasia, as well as inflammation. Moreover, the results demonstrate the feasibility of identifying tissue-specific transduction peptides capable of mediating efficient transduction in vivo.

Original languageEnglish (US)
Pages (from-to)295-305
Number of pages11
JournalMolecular Therapy
Issue number2
StatePublished - Aug 1 2003

Bibliographical note

Funding Information:
The authors thank Joan Nash, Sujin Wang, and Dr. Glen Papworth for their technical assistance. This work was partially supported by Contract AR-6-2225 and DK44935 from the National Institutes of Health and by grants from the Arthritis Foundation of the Western Chapter of Pennsylvania, the Muscular Dystrophy Association, the Cystic Fibrosis Foundation, and the Pittsburgh Foundation


Dive into the research topics of 'Identification of a synovial fibroblast-specific protein transduction domain for delivery of apoptotic agents to hyperplastic synovium'. Together they form a unique fingerprint.

Cite this